TapewireFind a company

person · Reporting owner

Boyd Peter E.

Disclosed activity across 1 company

Tapewire entity
49072
SEC CIK
0001739816

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Aquestive Therapeutics, Inc.AQST · Entity 5276Chief People OfficerSeptember 09, 2026September 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aquestive Therapeutics, Inc.

Report date September 09, 2026 · Filed September 10, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect284,024 Reported balance After 2026-09-09 transaction · row 1
1 source row

Row 1 · 2026-09-09 · Other · Acquired 2,293 · Balance 284,024

F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.

Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2027-06-08Direct0 Reported balance After 2026-09-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-09 · Other · Disposed 2,293 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 09, 2026 Filed Sep 10, 2026 13:21 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 OtherWarrant (Right to Buy) · Derivative 2,293 $0.00 Strike: $0.96 $0.00
Disclosure

SEC source: 0001214659-26-011541 · marketforms-73978.xml · derivative · entry 2

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,293 shares

Expires 2027-06-08

Read SEC document
September 09, 2026 Filed Sep 10, 2026 13:21 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 OtherCommon Stock 2,293 $0.96 $2,201.28
Disclosure

SEC source: 0001214659-26-011541 · marketforms-73978.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 284,024

F1 · shares: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.

F1 · price: Represents the exercise for cash of a Common Stock Purchase Warrant issued to the Reporting Person on June 8, 2022 pursuant to a Securities Purchase Agreement dated June 6, 2022. The warrant became exercisable on December 8, 2022, expires on June 8, 2027, and has an exercise price of $0.96 per share.

Read SEC document
May 05, 2026 Filed May 7, 2026 21:34 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 56,778 $4.18 $237,332.04
Disclosure

SEC source: 0001214659-26-005751 · marketforms-73068.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,731

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Read SEC document
March 10, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 SaleCommon Stock 29,814 $4.17 $124,413.82
Disclosure

SEC source: 0001214659-26-003147 · marketforms-72463.xml · nonDerivative · entry 2

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 338,509

F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F3 · price: This transaction was executed in multiple trades at prices ranging from $4.17 to $4.33. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 42,500 $4.29 Strike: $4.29 $182,325.00
Disclosure

SEC source: 0001214659-26-003147 · marketforms-72463.xml · derivative · entry 3

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,500

Underlying: Common Stock · 42,500 shares

Expires 2036-03-09

F4 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 09, 2026 Filed Mar 11, 2026 16:52 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-26-003147 · marketforms-72463.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,323

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
December 04, 2025 Filed Dec 5, 2025 18:06 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 20,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-25-017652 · marketforms-71415.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 288,323

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
October 15, 2025 Filed Oct 17, 2025 18:00 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 SaleCommon Stock 10,000 $7.00 $70,000.00
Disclosure

SEC source: 0001214659-25-015046 · marketforms-71047.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 268,323

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Read SEC document
September 26, 2025 Filed Sep 29, 2025 20:26 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 SaleCommon Stock 10,000 $6.30 $63,000.00
Disclosure

SEC source: 0001214659-25-014287 · marketforms-70873.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 278,323

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Read SEC document
September 05, 2025 Filed Sep 8, 2025 21:13 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 SaleCommon Stock 15,000 $5.30 $79,500.00
Disclosure

SEC source: 0001214659-25-013485 · marketforms-70566.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 288,323

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan previously adopted by the reporting person in this Form 4.

Read SEC document
March 09, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 7,681 $2.65 $20,354.65
Disclosure

SEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 3

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 303,323

F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 40,000 $0.00 Strike: $2.65 $0.00
Disclosure

SEC source: 0001214659-25-004222 · marketforms-68504.xml · derivative · entry 4

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-03-07

F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 6,624 $2.65 $17,553.60
Disclosure

SEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 2

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,004

F2 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 80,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-25-004222 · marketforms-68504.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 317,628

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2025 Filed Apr 13, 2026 19:54 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 60,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-26-004596 · marketforms-72925.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2028-03-07

F1 · security: This Form 4 was filed late due to an inadvertent administrative oversight.

F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).

F2 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).

Read SEC document
March 09, 2024 Filed Mar 12, 2024 17:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 Tax withholdingCommon Stock 8,370 $4.88 $40,845.60
Disclosure

SEC source: 0001214659-24-004394 · marketforms-65146.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,628

F1 · shares: Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Restricted Stock Units ("RSUs") previously granted to the Reporting Person.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 14:35 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 43,125 $0.00 Strike: $5.68 $0.00
Disclosure

SEC source: 0001214659-24-004303 · marketforms-64689.xml · derivative · entry 2

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,125

Underlying: Common Stock · 43,125 shares

Expires 2034-03-07

F3 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 14:35 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 86,250 $0.00 $0.00
Disclosure

SEC source: 0001214659-24-004303 · marketforms-64689.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,998

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

F2 · balance_after: The original Form 4, filed on 3/9/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares for 59,532 shares owned when in fact 59,748 shares of the Issuer's common stock were owned. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 216 shares.

Read SEC document
August 09, 2023 Filed Aug 9, 2023 20:30 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-010925 · marketforms-61885.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2026-05-05

F1 · derivative.exercise_price: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

F1 · derivative.exercise_date: Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Read SEC document
May 05, 2023 Filed May 5, 2023 20:00 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantPerformance Stock Units · Derivative 50,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-006555 · marketforms-61236.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2026-05-05

F1 · derivative.exercise_price: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

F1 · derivative.exercise_date: Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of Aquestive ("Company") common stock. The PSUs have a three-year Performance Period, and, to the extent earned, will vest 100% on the third anniversary of the grant date, subject to the grantee's continued employment or other service with the Company or any Subsidiary from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the three-year Performance Period is subject to increase or decrease based on the results of the Performance Price. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Read SEC document
March 09, 2023 Filed Mar 9, 2023 20:07 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0001214659-23-003695 · marketforms-59523.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · See Remark

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,532

F1 · shares: The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
November 04, 2022 Filed Nov 8, 2022 15:23 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 25,000 $0.00 Strike: $0.88 $0.00
Disclosure

SEC source: 0001214659-22-013282 · marketforms-57370.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-11-04

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
June 14, 2022 Filed Jun 15, 2022 14:24 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 5,000 $0.81 $4,050.00
Disclosure

SEC source: 0001628280-22-017186 · wf-form4_165530302948520.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,532

F1 · price: This transaction was executed in multiple transactions at the price of $0.81. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and price at which the transaction was effected.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:26 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseWarrant (Right to Buy) · Derivative 2,293 $0.13 Strike: $0.96 $298.09
Disclosure

SEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · derivative · entry 2

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,293

Underlying: Common Stock · 2,293 shares

Expires 2027-06-08

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13

Read SEC document
June 08, 2022 Filed Jun 10, 2022 21:26 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 2,293 $0.96 $2,201.28
Disclosure

SEC source: 0001628280-22-016872 · wf-form4_165489636547699.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,532

F1 · price: Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13

Read SEC document
March 10, 2022 Filed Mar 14, 2022 15:24 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 70,000 $0.00 Strike: $2.55 $0.00
Disclosure

SEC source: 0001214659-22-003895 · marketforms-55761.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2032-03-10

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 11, 2021 Filed Mar 15, 2021 21:10 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 35,000 $0.00 Strike: $5.30 $0.00
Disclosure

SEC source: 0001214659-21-003146 · marketforms-51877.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2031-03-11

F1 · derivative.exercise_date: The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 20:45 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 50,700 $0.00 Strike: $1.54 $0.00
Disclosure

SEC source: 0001214659-20-002746 · marketforms-48349.xml · derivative · entry 2

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,700

Underlying: Common Stock · 50,700 shares

Expires 2030-03-16

F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.

Read SEC document
March 16, 2020 Filed Mar 18, 2020 20:45 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 2,000 $1.50 $3,000.00
Disclosure

SEC source: 0001214659-20-002746 · marketforms-48349.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,239

Read SEC document
August 12, 2019 Filed Aug 13, 2019 20:30 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 600 $3.81 $2,286.00
Disclosure

SEC source: 0001214659-19-005182 · marketforms-45478.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Bus. Process & Info. Tech.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,239

Read SEC document
February 28, 2019 Filed Mar 4, 2019 21:47 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantNon-Qualified Stock Option (right to buy) · Derivative 30,000 $0.00 Strike: $8.05 $0.00
Disclosure

SEC source: 0001214659-19-001751 · marketforms-44352.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-02-28

F1 · derivative.exercise_date: The units subject to the Award shall vest 25% 1st year, 25% 2nd year and 50% 3rd year on the commencement anniversaries.

Read SEC document
November 21, 2018 Filed Nov 26, 2018 18:35 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 PurchaseCommon Stock 200 $9.98 $1,996.00
Disclosure

SEC source: 0001140361-18-043649 · form4.xml · nonDerivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,639

Read SEC document
July 24, 2018 Filed Jul 27, 2018 01:14 UTC Aquestive Therapeutics, Inc. AQST · Entity 5276 GrantStock Option (Right to Purchase) · Derivative 36,223 $0.00 Strike: $15.00 $0.00
Disclosure

SEC source: 0001140361-18-033746 · form4.xml · derivative · entry 1

Boyd Peter E. · CIK 0001739816 · SVP-Operations/Value Delivery

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,223

Underlying: Common Stock · 36,223 shares

Expires 2028-07-24

F1 · derivative.exercise_date: The shares underlying the options vest as follows: 25% of the underlying shares vest on the first anniversary of the grant date, 25% of the underlying shares vest on the second anniversary of the grant date and the remaining 50% of the underlying shares vest on the third anniversary of the grant date, subject in each case to Mr. Boyd's continuous service with the Issuer from the grant date through the applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.